- Research article
- Open Access
Higher proliferation of peritumoral endothelial cells to IL-6/sIL-6R than tumoral endothelial cells in hepatocellular carcinoma
BMC Cancer volume 15, Article number: 830 (2015)
This study aimed to explore the responses to the interleukin-6 (IL-6)/soluble interleukin-6 receptor (sIL-6R) complex in peritumoral endothelial cells (PECs) and tumor endothelial cells (TECs), as well as determine the signaling pathways in the angiogenesis of hepatocellular carcinoma (HCC).
The expression of IL-6, IL-6R, gp130, CD68, HIF-1α, and microvessel density (MVD) were assessed with an orthotopic xenograft model in nude mice. ECs were incubated under hypoxic conditions to detect IL-6 and gp130. The proliferation of PECs and TECs in the presence of IL-6 and sIL-6R, as well as the expression of gp130, JAK2/STAT3, PI3K/AKT in endothelial cells were measured.
Peritumoral IL-6, IL-6R, gp130, CD68, and HIF-1α expression, as well as MVD, gradually increased during tumor growth. Hypoxia could directly induce IL-6 expression, but not gp130 in PECs. The co-culture of IL-6/sIL-6R induced much higher PEC proliferation and gp130 expression, as well as the elevated phosphorylation of JAK2 and STAT3, however not the phosphorylation of PI3K and AKT.
PECs exhibited higher proliferation in response to IL-6/sIL-6R co-treatment compared with TECs in HCC via the up-regulation of gp130 /JAK2/STAT3. PEC and its associated peritumoral angiogenesis microenvironment may be a potential novel target for anti-angiogenic treatment.
Angiogenesis is a fundamental event in the process of hepatocellular carcinoma (HCC) growth and metastatic dissemination [1, 2]. The current understanding of angiogenesis is mostly focused on tumor angiogenesis. However, reports from our group and others have implied that more pro-angiogenic factors are present in pertitumoral liver tissue compared with those in tumor tissue [3–7]. Furthermore, peritumoral angiogenesis can predict tumor metastasis and patient prognosis [6, 8, 9]. Therefore, the activation and proliferation of endothelial cells (ECs) to develop new vessels from pre-existing ones are vital for the process of angiogenesis. ECs may be strictly classified into tumor ECs (TECs) and peritumoral ECs (PECs). TECs and PECs should be specifically studied in terms of their different biological functions during angiogenesis and response to pro-angiogenic factors.
TECs and PECs are known to possess different characteristics in terms of their morphology , pathophysiology , cytogenetics , epigenetics , and gene expression . Our previous study showed that TECs demonstrate increased apoptotic resistance, motility, and other pro-angiogenic properties, with the increased ability to adhere to tumor cells and survive in the tumor environment, compared with PECs . These results suggested that the differences between PECs and TECs may account for their different levels of efficiency in therapy, such as increased resistance to adriamycin, 5-fluorouracil, and sorafenib in TECs . Therefore, an improved understanding of the different signaling events that mediate the response to pro-angiogenic factors between TECs and PECs will lead to the development of improved anti-angiogenesis therapies for HCC.
Interleukin-6 (IL-6) plays a role in primary tumor progression . The genetic signature derived from non-tumor liver tissue may reflect the promoting effects of IL-6 on the development of metachronous tumors that are independent from the primary resected HCC [17, 18]. Tumor-derived IL-6 is known to promote EC proliferation and new blood vessel generation that support the high metabolic demands of tumor cells. The cell signaling pathway of IL-6 for EC proliferation has been previously studied, and the formation of the IL-6/IL-6R/gp130 complex on the EC surface can induce PI3K/AKT or JAK2/STAT3 activation and cell proliferation [19, 20]. ECs lack IL-6R, and soluble IL-6R eventually plays an important role in EC proliferation via the trans-signaling pathway; consequently, signaling occurs after the formation of the IL-6/sIL-6R/gp130 complex on the EC surface [21, 22]. However, the aforementioned functional studies were mostly conducted with established cell lines, such as the human umbilical vein ECs (HUVECs). The use of HUVECs causes an obvious disadvantage because these cells are derived from large vessels that lack the typical characteristics of TECs and PECs. Therefore, the characterization of different responses to IL-6/sIL-6R treatment in TECs and PECs, as well as their respective signaling pathways, may reveal EC characterization.
A prevalent paradigm in tumor biology is that TECs may have a much higher proliferation rate when responding to pro-angiogenic factors, such as IL-6 or sIL-6R. This paradigm was challenged by the present study. Our results showed that PECs had much higher levels of cell proliferation when co-cultured with IL-6/sIL-6R by automatically up-regulating their cell surface gp130 levels in vitro and activating JAK2/STAT3 signaling pathway, which had no effect on the PI3K/AKT signaling pathways. Our results also demonstrated that IL-6 secretion by PECs was induced by peritumoral hypoxia, and the increased IL-6 levels contributed to the much higher proliferation of the cells.
Cell lines and culture conditions
PECs and TECs were obtained from surgical HCC specimens and their surrounding normal liver tissue immediately after removal from patients, as previously described in our laboratory . ECs were isolated from the cell suspension by anti-CD105 antibodies coupled to magnetic beads (Miltenyi Biotech, Germany) and magnetic cell sorting with the MACS system (Miltenyi Biotech,, Germany) . Cells were grown in complete EBM-2 medium supplemented with 10 % fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin. ECs between passages 1 and 6 were used in the subsequent experiments within six months after resuscitation. The study was approved by the Xinhua Hospital Research Ethics Committee. Informed consent was obtained according to the committee's regulations.
Six-week-old male BALB/c nu/nu nude mice, weighing approximately 20 g each (Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China), were housed in laminar flow cabinets under specific pathogen-free conditions. Orthotopic implantation of human HCC cell line HCCLM3 in BALB/c mice was performed as previously described [23–25]. The mice were cared and handled in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. The experimental protocol was approved by the Shanghai Medical Experimental Animal Care Committee. To study EC proliferation and angiogenesis-related genes in peritumoral tissue during tumor growth, 18 mice of the HCC tumor model was established by orthotopic implantation of a histologically intact tumor tissue derived from HCCLM3 cell line, and 6 mice were killed at the end of the 2, 5 and 7wk after tumor injection respectively.
Tissue microarray and immunohistochemistry (IHC)
We constructed a tumor microarray (Shanghai Biochip Co., Ltd, Shanghai, China) as described in our previous study . After reviewing HE-stained slides for the location of tumor tissue and tissue adjacent to tumor (TAT) with the distance of 2 cm away from tumor, we constructed TMA slides (collaborated with Shanghai Biochip Company, Ltd, Shanghai, China). Two cores were taken from each formalin-fixed, paraffin-embedded HCC and TAT sample, respectively, by using punch cores that measured 1.0 mm in greatest dimension from the nonnecrotic area of tumor foci and TAT. The following primary antibodies were used: mouse monoclonal anti-IL-6, anti-IL-6R, and anti-gp130 antibodies (Abcam, Cambridge, MA, USA), rabbit polyclonal anti-CD31 and anti-HIF-1α antibodies (Abcam, Cambridge, MA, USA), and mouse monoclonal anti-CD68 antibody (1:100; Zymed Laboratories, San Francisco, CA, USA). The density of positively stained cells was measured as specified in our previous study . The integrated optical density was determined using Image-Pro Plus v6.2 software (Media Cybernetics, Inc., Bethesda, MD, USA) with the same setting for all the slides. To quantify the mean microvessel density (MVD), five fields at 100× magnification in the CD31-stained “hotspot” were photographed. The MVD was quantified as the ratio of the CD31-positive area to the total area.
Reverse transcription PCR (RT-PCR) analysis
The mRNA levels of IL-6, IL-6R, and gp130 in the peritumoral liver tissue, as well as those of IL-6 and gp130 in the PECs and TECs, were detected as follows. Total RNA was extracted following the manufacturer’s protocol (Invitrogen). Real-time RT-PCR analysis for quantification was performed using an SYBR Premix Ex Taq™ (perfect real time; TaKaRa). The relative mRNA expression was normalized to that of β-actin. The relative amount of tissue mRNA was standardized by the amount of β-actin mRNA, and expressed as − △CT = CT(factor) − CT(β-actin). The ratio of the number of mRNA copies to the number of β-actin mRNA copies was then calculated as 2–△CT × K, where K is a constant. The primers for RT-PCR are listed in Additional file 1: Table S1.
Western blot analysis
After 24 and 48 h of incubation with different stimulatory agents (IL-6, sIL-6R, IL-6 and sIL-6R), the PECs and TECs were harvested and lysed or homogenized for Western blot analysis. The primary antibodies for the analysis included IL-6, IL-6R, gp130, p-JAK2 (Y1007/1008), JAK2, p-STAT3(Y705), STAT3, p-PI3K(Y607), PI3K, p-Akt(S473), Akt and GAPDH (Cell Signaling Technology, Beverly, MA). Specific protein expression levels were normalized to the GAPDH protein. All experiments were performed in triplicate and densitometric analysis was performed for the statistical significance.
The primary antibodies used were rabbit polyclonal gp130 (1:100; Santa Cruz, CA, USA) and rabbit monoclonal IL-6 (1:200; Abcam, Cambridge, MA, USA) antibodies. The primary antibody was detected by the secondary antibodies of anti-rabbit IgG-TR (Texas Red; Abcam) and anti-mouse IgG-FITC (Abcam). Cells were incubated with the respective primary antibody overnight at 4 °C. Sections were washed three times in PBS, followed by incubation with the secondary antibody for 1 h at room temperature. Samples were analyzed with an inverted fluorescence microscope (Olympus IX51) equipped with an Olympus Qcolor 3 digital camera (Olympus).
Cell proliferation assay
The cultured PECs or TECs were plated in triplicate into 96-well plates containing EBM-2 medium for 10 h. To detect the cellular response to IL-6 (20 ng/ml) and sIL-6R (100 ng/ml) treatment (R&D Systems, Minneapolis, MN, USA), cells were cultured for 24, 48, and 72 h in medium containing different drugs at the indicated concentrations. The Cell Counting Kit-8 (CCK-8) (Dojindo Laboratories, Kumamoto, Japan) was used to determine cell viability. All experiments were performed in triplicate.
Cell culture and hypoxia
PECs and TECs were incubated in 37 °C under a humidified atmosphere (5 % CO2) for 24 and 48 h in the presence or absence of cobalt chloride (CoCl2, 100 μmol/L), which was used to mimic the effects of hypoxia by its minimal effect on cell viability Both cell types were then harvested for detection of IL-6 and gp130 expression by immunocytochemistry and RT-PCR.
All statistical analyses were performed with SPSS version 16.0 software. The Spearman rank correlation coefficient was used to analyze the correlations among parameters. Quantitative variables were expressed as the mean ± standard deviation, and analyzed with the t-test. P < 0.05 was considered statistically significant.
Gradually increased levels of IL-6 IL-6R, gp130, CD68, and MVD in peritumoral liver tissue
Compared with HCC tumor tissue, several EC proliferation and angiogenesis-related genes in peritumoral tissue were gradually up-regulated during seven weeks of tumor growth, including IL-6, IL-6R, and gp130, which was confirmed by RT-PCR (using mouse-specific primers), IHC staining (Fig. 1a, c) and Western blot (Fig. 1f). The results showed more than a twofold change in the expression ratio of seven weeks/five weeks. Specifically, the expression of IL-6 (3.45-fold), IL-6R (2.35-fold), and gp130 (4.21-fold) changed. The expression levels of representative mice after seven weeks of tumor growth were visualized by IHC (Fig. 1a), and the corresponding expression curve after seven weeks was shown in Fig. 1c. The Western blot analysis also revealed the similar trend of IL-6, IL-6R and gp130 during tumor growth (Fig. 1f). Peritumoral MVD followed a similar trend after seven weeks of tumor growth, which was confirmed by IHC (20.2 % ± 0.9 % vs. 15.6 % ± 2.4 % for seven and five weeks, respectively; P = 0.021, Fig. 1e). Previous studies stated that macrophages contribute to sIL-6R secretion [26, 27]. We found that peritumoral CD68(+) macrophages were also up-regulated on the seventh week of tumor growth (Fig. 1a); this change was significantly associated with peritumoral IL-6R (rr = 0.556, P = 0.001).
The expression pattern of all the factors (IL-6, IL-6R, gp130, and CD68) was not similar among the tumor tissues, such that all the factors were gradually up-regulated until five weeks. Subsequently, all the factors were down-regulated, and RT-PCR indicated that the expression ratios of seven weeks/five weeks of IL-6, IL-6R, and gp130 in tumor growth decreased by 0.43-fold, 0.47-fold, and 0.33-fold, respectively. These results were also confirmed by IHC (Fig. 1b, d) and Western blotting (Fig. 1f). Similarly, the MVD was down-regulated from that after five weeks of tumor growth (13.5 % ± 1.4 % vs. 28.6 % ± 5.8 % for seven and five weeks, respectively; P = 0.014; Fig. 1d). These results were much lower than that of peritumoral MVD (P = 0.004).
Hypoxia induced IL-6 expression in PECs
To further elucidate the peritumoral microenvironment during the up-regulation of IL-6, we stained peritumoral tissues with the hypoxia indicator HIF-1α. The peritumoral expression of IL-6 gradually increased during tumor growth (Fig. 1a, c). Peritumoral HIF-1α were in accordance with the peritumoral IL-6 expression (rr = 0.721, P = 0.004). To determine whether hypoxia can directly up-regulate the expression of IL-6 in PECs, we treated PECs to hypoxic or normoxic conditions for 24 and 48 h. The results demonstrated that IL-6 was significantly up-regulated in PECs under hypoxic conditions for 48 h, which was confirmed by immunocytochemistry (Fig. 2a), IHC (Fig. 2b), and RT-PCR (mean − △CT, −0.01 ± 0.003 vs. –0.17 ± 0.052 for hypoxic and normoxic conditions, P = 0.014, Fig. 2c). However, we found that hypoxia had no direct effect on PEC proliferation in vitro for 24 and 48 h (1.17 ± 0.01 vs. 1.16 ± 0.01, P = 0.714 and 2.23 ± 0.01 vs. 2.25 ± 0.02, P = 0.628 under hypoxic and normoxic conditions for 24 and 48 h, respectively; cell proliferation was evaluated by the CCK-8 assay).
Hypoxia did not up-regulate gp130 in PECs
PECs were further characterized for the distinct expression of endothelial surface markers: IL-6R(−) and gp130(+). The expression levels of endothelial markers were tested at the first, third, and fifth passages, and similar results were confirmed during cell culture. We investigated the expression levels of gp130 in PECs under hypoxic conditions. The levels of gp130 were not affected by hypoxia for 24 and 48 h based on immunocytochemistry (gp130 expression under hypoxic and normoxic conditions for 48 h was shown in Fig. 2a) and RT-PCR [mean − △CT: −12.5 ± 0.04 vs. −13.1 ± 0.05 (P = 0.825) and −10.7 ± 0.05 vs. −9.9 ± 0.07 (P = 0.545) under hypoxic and normoxic conditions for 24 and 48 h, respectively, Fig. 2c].
Effect of IL-6 and sIL-6R on the proliferation of PECs and TECs
We subsequently determined the effects of IL-6 and sIL-6R on EC proliferation, and found that neither IL-6 nor sIL-6R alone had an effect on the proliferation of PECs and TECs (Fig. 3). To determine whether the presence of both IL-6 and sIL-6R can induce the proliferation of PECs and TECs, we co-cultured both cell types with IL-6 and sIL-6R. Interestingly, the proliferation of both PECs and TECs was much higher when the cells were grown together with IL-6 and sIL-6R compared with that of cells grown with either IL-6 or sIL-6R for 48 h and 72 h (especially predominant for 48 h), and no obvious different was observed in 24 h. Therefore, cell proliferation increased in response to the co-culture environment. Further, PECs showed a much higher rate of proliferation in response to the co-culture environment than TECs [2.65 ± 0.01 vs. 2.25 ± 0.02 for PECs under the co-cultured and vehicle conditions for 48 h, respectively (P = 0.0004); 1.50 ± 0.01 vs. 1.37 ± 0.01 for TECs under the co-cultured and vehicle conditions for 48 h, respectively (P = 0.029)]; cell proliferation was evaluated by the CCK-8 assay; Fig. 3, Table 1].
Effects of IL-6 or sIL-6R on the expression of gp130 and JAK2/STAT3, PI3K/AKT in PECs and TECs
IL-6 or sIL-6R alone had no effect on the proliferation of ECs. Considering the predominant higher proliferation of ECs when co-culture with both IL-6 and sIL-6R for 48 h, we examined the effects of IL-6 or sIL-6R on the cell signaling pathways in EC proliferation for 48 h, in terms of the gp130, JAK2/STAT3 and PI3K/AKT expression. First, we found the administration of IL-6 or sIL-6R alone could not promote the expression of all the factors (Fig. 4), however, co-culture with both IL-6 and sIL-6R lead to a synergistic increase in gp130 expression, and this value was especially much higher in PECs with respect to the mRNA (RT-PCR, mean − △CT: −14.9 ± 0.22 vs. −19.5 ± 0.15 for IL-6/sIL-6R vs. control in PECs, P = 0.0005; −16.2 ± 0.11 vs. −18.4 ± 0.22 for IL-6/sIL-6R vs. control in TECs, P = 0.045) and protein levels by Western blot analysis (Fig. 4). Furthermore, phosphorylation of JAK2 and STAT3 in PECs were significantly increased when co-culture with both IL-6 and sIL-6R for 48 h, and the phosphorylation of both factors were not so obvious for 48 h in TECs, while phosphorylation of PI3K and AKT were not affected in both cells (Fig. 4).
This study reported that PECs demonstrated a much higher level of cell proliferation under co-culture with IL-6/sIL-6R by automatically up-regulating their cell surface gp130 proteins and increased phosphorylation of JAK2 and STAT3. The present study confirmed that hypoxia induced elevated IL-6 levels in PECs, however, no direct effects on cell proliferation were observed. Animal studies confirmed that peritumoral MVD was much higher than tumor MVD when tumors were large. Therefore, PECs and their associated peritumoral angiogenesis microenvironment are worthy of attention.
The novel finding in this study is that peritumoral angiogenesis was much higher than tumor angiogenesis when tumors had increased in size. The peritumoral angiogenesis microenvironment was much richer in terms of its much higher levels of hypoxia, IL-6, IL-6R, gp130, and CD68(+) macrophages. The present study showed that PEC proliferation relied on the up-regulation of IL-6/sIL-6R and gp130, which was in accordance with peritumoral hypoxia. Previous studies showed that anti-angiogenic factors exert an inhibitory effect on HCC growth mainly through anti-tumor angiogenesis [23, 28–31]. However, higher peritumoral angiogenesis is more important for intrahepatic metastasis during the progress of tumor growth. Attention should be given to peritumoral angiogenesis as the major therapeutic target.
In the present study, higher peritumoral IL-6 levels were proven to be derived from PECs. The IL-6 levels were induced by peritumoral hypoxia and associated with large tumor sizes. Therefore, we postulated that the compression effect on peritumoral tissues, as induced by the primary tumor, could create the peritumoral hypoxia environment, which contributed to IL-6 expression in peritumoral tissue and subsequent PEC proliferation.
IL-6 plays several roles in the pathway. Combining the membrane containing IL-6R and gp130 forms the IL-6/IL-6R/gp130 complex, which activates the JAK2/STAT3 or PI3K/AKT pathway and subsequent biological activities [19, 20], such as EC proliferation. Our present study found that IL-6 alone was unable to directly stimulate TEC and PEC proliferation. The lack of IL-6R on the surface of ECs suggested that IL-6 may exert its effect on ECs by combining with sIL-6R, and then it combines with the EC surface gp130 and ultimately activates the JAK2/STAT3 or PI3K/AKT pathway via the trans-signaling pathway. Our in vitro study confirmed that sIL-6R was an important factor of the vascular EC proliferation signaling pathway, which was consistent with other studies [21, 22], however, we also found that only the combination of IL-6 and sIL-6R could induce EC proliferation via JAK2/STAT3 signaling pathways however not the PI3K/AKT pathway. Previous studies have proven that macrophages or neutral granulocytes can contribute to sIL-6R secretion [26, 27, 32]. We found that the increased extensive distribution of macrophages was also associated with IL-6R. However, whether or not IL-6R is derived from macrophages requires further investigation.
In addition, we found that PECs had a stronger response to co-culture with IL-6 and sIL-6R compared with TECs. This result may be caused by the different cell signaling pathways between PECs and TECs during EC proliferation. gp130 is an important cell surface factor that is crucial for cell proliferation. Interestingly, we found that gp130 could be directly up-regulated in ECs after the administration of both IL-6 and sIL-6R. However, hypoxia had no direct effect on the expression of surface gp130 on PECs, which was in contrast to previous studies that stated that gp130 is controlled by HIF-1α [33, 34], and the controversial may be attributed to the fact that HIFs may differentially regulate the expression of the same angiogenic gene in different cell types; In our present study, the mechanism of gp130 expression unmodulated in PECs under hypoxia condition may be due to its distinct cell surface markers: IL-6R(−) and gp130 (+). In vivo study, only co-administration of both IL-6 and sIL-6R could lead to a synergistic increase in gp130 expression, which indicated that the up-regulation may be associated with effect of both IL-6 and IL-6R, and the elevated IL-6 on PECs by hypoxia could not alone up-regulate gp130 expression on PEC cell without IL-6R, and instead, the elevated peritumoral sIL-6R deriving from the macrophages together with elevated peritumoral IL-6 could lead to the higher expression of gp130 in peritumoral tissue, which had no direct correlation with peritumoral hypoxia.
The PECs comprise the key members of the peritumoral angiogenesis microenvironment. Previous studies suggested that the differences in the molecular phenotype of vascular ECs in normal and diseased tissues leads to different functions in both cell types . This phenomenon was confirmed by our studies between PECs and TECs. The optimized immune magnetic sorting method allowed us to successfully obtain PECs with a high level of purity. These cells could be successfully passed in culture and used in the associated angiogenesis research studies [15, 36]. In the present study, the automatic up-regulation of gp130 as well as the increased phosphorylation of JAK2 and STAT3 in response to the combination of IL-6 and sIL-6R in PECs may also explain its more pro-angiogenic properties. PECs may be more sensitive to the anti-angiogenesis therapy target at IL-6/sIL-6R or gp130/JAK2/STAT3.
This study demonstrated that PECs and TECs differed in their mode of angiogenesis. Although both cell types demonstrated proliferation only under co-stimulation with IL-6 and sIL-6R, the PECs showed a much higher proliferation rate, which was related to the automatic up-regulation of cell surface gp130 in PECs, as well as the increased phosphorylation of JAK2 and STAT3. In addition, the PI3K/AKT signaling pathways was not associated with the cells. Elevated peritumoral IL-6 expression in PECs, as well as peritumoral IL-6R expression induced by peritumoral hypoxia, could promote PEC proliferation and peritumoral angiogenesis. Furthermore, given the sensitivity of PECs to IL-6/sIL-6R, the PECs are the potential new targets for anti-angiogenic treatments.
Soluble interleukin-6 receptor
Peritumoral endothelial cells
Tumor endothelial cells
Human umbilical vein ECs
Integrated optical density
Cell counting kit-8
Tris buffered saline
Phosphate buffered saline
Otrock ZK, Makarem JA, Shamseddine AI. Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis. 2007;38:258–68.
Wang WQ, Liu L, Sun HC, Fu YL, Xu HX, Chai ZT, et al. Tanshinone IIA inhibits metastasis after palliative resection of hepatocellular carcinoma and prolongs survival in part via vascular normalization. J Hematol Oncol. 2012;5:69.
Yu D, Zhuang L, Sun X, Chen J, Yao Y, Meng K, et al. Particular distribution and expression pattern of endoglin (CD105) in the liver of patients with hepatocellular carcinoma. BMC Cancer. 2007;7:122.
Yu GR, Kim SH, Park SH, Cui XD, Xu DY, Yu HC, et al. Identification of molecular markers for the oncogenic differentiation of hepatocellular carcinoma. Exp Mol Med. 2007;39:641–52.
Zhuang PY, Shen J, Zhu XD, Lu L, Wang L, Tang ZY, et al. Prognostic roles of cross-talk between peritumoral hepatocytes and stromal cells in hepatocellular carcinoma involving peritumoral VEGF-C, VEGFR-1 and VEGFR-3. PLoS One. 2013;8:e64598.
Jia JB, Zhuang PY, Sun HC, Zhang JB, Zhang W, Zhu XD, et al. Protein expression profiling of vascular endothelial growth factor and its receptors identifies subclasses of hepatocellular carcinoma and predicts survival. J Cancer Res Clin Oncol. 2009;135:847–54.
Xu HX, Zhu XD, Zhuang PY, Zhang JB, Zhang W, Kong LQ, et al. Expression and prognostic significance of placental growth factor in hepatocellular carcinoma and peritumoral liver tissue. Int J Cancer. 2010;128:1559–69.
Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006;10:99–111.
Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol. 2008;26:2707–16.
McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med. 2003;9:713–25.
Hagendoorn J, Tong R, Fukumura D, Lin Q, Lobo J, Padera TP, et al. Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis. Cancer Res. 2006;66:3360–4.
Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, Morton CC, et al. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res. 2004;64:8249–55.
Grover AC, Tangrea MA, Woodson KG, Wallis BS, Hanson JC, Chuaqui RF, et al. Tumor-associated endothelial cells display GSTP1 and RARbeta2 promoter methylation in human prostate cancer. J Transl Med. 2006;4:13.
St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, et al. Genes expressed in human tumor endothelium. Science. 2000;289:1197–202.
Xiong YQ, Sun HC, Zhang W, Zhu XD, Zhuang PY, Zhang JB, et al. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res. 2009;15:4838–46.
Tang S, Yuan Y, He Y, Pan D, Zhang Y, Liu Y, et al. Genetic polymorphism of interleukin-6 influences susceptibility to HBV-related hepatocellular carcinoma in a male Chinese Han population. Hum Immunol. 2014;75:297–301.
Hoshida Y, Sangiovanni A, et al. Gene expression signature predicts outcome of liver cirrhosis. Hepatology. 2009;50:312A.
Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008;359:1995–2004.
Ara T, Declerck YA. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer. 2010;46:1223–31.
Jee SH, Chu CY, Chiu HC, Huang YL, Tsai WL, Liao YH, et al. Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and PI3-kinase/Akt pathways. J Invest Dermatol. 2004;123:1169–75.
Jones SA, Richards PJ, Scheller J, Rose-John S. IL-6 transsignaling: the in vivo consequences. J Interferon Cytokine Res. 2005;25:241–53.
Knupfer H, Preiss R. sIL-6R: more than an agonist? Immunol Cell Biol. 2008;86:87–91.
Wang L, Tang ZY, Qin LX, Wu XF, Sun HC, Xue Q, et al. High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology. 2000;32:43–8.
Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 2006;132:458–65.
Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med. 2003;9:416–23.
Horiuchi S, Koyanagi Y, Zhou Y, Miyamoto H, Tanaka Y, Waki M, et al. Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur J Immunol. 1994;24:1945–8.
Briso EM, Dienz O, Rincon M. Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells. J Immunol. 2008;180:7102–6.
Wang L, Wu WZ, Sun HC, Wu XF, Qin LX, Liu YK, et al. Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg. 2003;7:587–94.
Wada H, Nagano H, Yamamoto H, Arai I, Ota H, Nakamura M, et al. Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins. Oncol Rep. 2007;18:801–9.
von Marschall Z, Scholz A, Cramer T, Schafer G, Schirner M, Oberg K, et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst. 2003;95:437–48.
Zhuang PY, Zhang JB, Zhang W, Zhu XD, Liang Y, Xu HX, et al. Long-term interferon-alpha treatment suppresses tumor growth but promotes metastasis capacity in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2010;136:1891–900.
Chalaris A, Rabe B, Paliga K, Lange H, Laskay T, Fielding CA, et al. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood. 2007;110:1748–55.
Savale L, Tu L, Rideau D, Izziki M, Maitre B, Adnot S, et al. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res. 2009;10:6.
Fuertes M, Gerez J, Haedo M, Giacomini D, Paez-Pereda M, Labeur M, et al. Cytokines and genes in pituitary tumorigenesis: RSUME role in cell biology. Front Horm Res. 2010;38:1–6.
Aird WC. Mechanisms of endothelial cell heterogeneity in health and disease. Circ Res. 2006;98:159–62.
Xiong YQ, Sun HC, Zhu XD, Zhang W, Zhuang PY, Zhang JB, et al. Bevacizumab enhances chemosensitivity of hepatocellular carcinoma to adriamycin related to inhibition of survivin expression. J Cancer Res Clin Oncol. 2011;137:505–12.
This study was supported by grants from the National Natural Science Foundation of China (No.81101851) and General Program of Shanghai Science and Technology Commission (No.13ZR1426600).
The authors declare that they have no competing interests.
PYZ carried out the studies, participated in the sequence alignment and drafted the manuscript. PYZ, JS, ZHT, JDW, XPZ, YBL, ZWQ performed the experiments and collected data as well as patient information. PYZ and JS participated in the design of the study and performed the statistical analysis. PYZ conceived of the study, and participated in its design and coordination and JS helped to draft the manuscript. All authors read and approved the final manuscript.
About this article
Cite this article
Zhuang, P., Wang, J., Tang, Z. et al. Higher proliferation of peritumoral endothelial cells to IL-6/sIL-6R than tumoral endothelial cells in hepatocellular carcinoma. BMC Cancer 15, 830 (2015). https://doi.org/10.1186/s12885-015-1763-2
- Peritumoral endothelial cell
- Tumor endothelial cell